


2nd Edition

# DIAGNOSTIC PATHOLOGY *of* INFECTIOUS DISEASE



Richard L. Kradin

ELSEVIER

Материал, защищенный авторским правом

# Diagnostic Pathology of Infectious Disease

# Diagnostic Pathology of Infectious Disease

*Second Edition*

**Richard L. Kradin, MD, DTM&H**

Associate Pathologist and Associate Physician  
Department of Pathology and Pulmonary/Critical Care Unit  
Massachusetts General Hospital  
Associate Professor in Pathology and Associate Professor in Medicine  
Harvard Medical School  
Boston, Massachusetts

ELSEVIER

ELSEVIER

1600 John F. Kennedy Blvd.  
Ste 1800  
Philadelphia, PA 19103-2899

DIAGNOSTIC PATHOLOGY OF INFECTIOUS DISEASE,  
SECOND EDITION

ISBN: 978-0-323-44585-6

Copyright © 2018 by Elsevier, Inc. All rights reserved.

No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval system, without permission in writing from the publisher. Details on how to seek permission, further information about the Publisher's permissions policies and our arrangements with organizations such as the Copyright Clearance Center and the Copyright Licensing Agency, can be found at our website: [www.elsevier.com/permissions](http://www.elsevier.com/permissions).

This book and the individual contributions contained in it are protected under copyright by the Publisher (other than as may be noted herein).

#### Notices

Knowledge and best practice in this field are constantly changing. As new research and experience broaden our understanding, changes in research methods, professional practices, or medical treatment may become necessary.

Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds, or experiments described herein. In using such information or methods they should be mindful of their own safety and the safety of others, including parties for whom they have a professional responsibility.

With respect to any drug or pharmaceutical products identified, readers are advised to check the most current information provided (i) on procedures featured or (ii) by the manufacturer of each product to be administered, to verify the recommended dose or formula, the method and duration of administration, and contraindications. It is the responsibility of practitioners, relying on their own experience and knowledge of their patients, to make diagnoses, to determine dosages and the best treatment for each individual patient, and to take all appropriate safety precautions.

To the fullest extent of the law, neither the Publisher nor the authors, contributors, or editors, assume any liability for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein.

Previous edition copyrighted 2010.

#### Library of Congress Cataloging-in-Publication Data

Names: Kradin, Richard L., editor.

Title: Diagnostic pathology of infectious disease / [edited by] Richard L. Kradin.

Description: Second edition. | Philadelphia, PA : Elsevier, [2018] | Includes bibliographical references and index.

Identifiers: LCCN 2017007825 | ISBN 9780323445856

Subjects: | MESH: Communicable Diseases--diagnosis | Communicable Diseases--pathology | Clinical Laboratory Techniques

Classification: LCC RA643 | NLM WC 100 | DDC 616.9--dc23 LC record available at <https://lccn.loc.gov/2017007825>

*Content Strategist:* Kayla Wolfe

*Senior Content Development Manager:* Katie DeFrancesco

*Publishing Services Manager:* Patricia Tannian

*Senior Project Manager:* Amanda Mincher

*Design Direction:* Teresa McBryan

Printed in China

Last digit is the print number: 9 8 7 6 5 4 3 2 1



Working together  
to grow libraries in  
developing countries

[www.elsevier.com](http://www.elsevier.com) • [www.bookaid.org](http://www.bookaid.org)

*I dedicate the second edition of this textbook to my colleagues in the departments of  
Pathology and Medicine at the Massachusetts General Hospital.*



# Contributors

**H. Thomas Aretz, MD**

Associate Professor of Pathology  
Harvard Medical School  
Vice President, Global Programs  
Partners HealthCare International  
Affiliate Pathologist  
Massachusetts General Hospital  
Boston, Massachusetts

**Sandra Camelo-Piragua, MD**

Clinical Assistant Professor of Pathology  
University of Michigan  
Ann Arbor, Michigan

**Norman C. Charles, MD**

Clinical Professor of Ophthalmology and Pathology  
Director, Ophthalmic Pathology, Bellevue Hospital Center  
New York University Langone Medical Center  
Director, Ophthalmic Pathology, Bellevue Hospital Center  
New York, New York

**Elizabeth G. Demicco, MD, PhD**

Assistant Professor of Pathology  
Mount Sinai Hospital  
New York, New York

**Vikram Deshpande, MBBS**

Associate Pathologist  
Massachusetts General Hospital  
Associate Professor of Pathology  
Harvard Medical School  
Boston, Massachusetts

**Ralph C. Eagle Jr., MD**

Director, Department of Pathology  
Wills Eye Hospital  
Philadelphia, Pennsylvania

**Alton B. Farris III, MD**

Associate Professor and Director  
Laboratory of Nephropathology and Electron Microscopy  
Department of Pathology  
Emory University  
Atlanta, Georgia

**Judith A. Ferry, MD**

Professor of Pathology  
Harvard Medical School  
Director of Hematopathology  
Department of Pathology  
Massachusetts General Hospital  
Boston, Massachusetts

**Jay A. Fishman, MD**

Professor of Medicine  
Harvard Medical School  
Director  
Transplantation Infectious Disease and Compromised Host  
Service  
Massachusetts General Hospital  
Boston, Massachusetts

**Robert P. Hasserjian, MD**

Associate Professor of Pathology  
Massachusetts General Hospital  
Harvard Medical School  
Boston, Massachusetts

**E. Tessa Hedley-Whyte, MD**

Professor of Pathology  
CS Kubik Laboratory for Neuropathology  
Massachusetts General Hospital  
Harvard University  
Boston, Massachusetts

**A. John Iafrate, MD, PhD**

Pathologist  
Massachusetts General Hospital  
Professor of Pathology  
Harvard Medical School  
Boston, Massachusetts

**Frederick A. Jakobiec, MD, DSc**

Director, David G. Cogan Ophthalmic Pathology Laboratory  
Department of Ophthalmology  
Massachusetts Eye and Ear Infirmary  
Boston, Massachusetts

**Matthew M. Johnson, MD**

Pathologist  
Carolinas Pathology Group  
Charlotte, North Carolina

**Susan V. Kattapuram, MD**

Associate Professor of Radiology  
Massachusetts General Hospital  
Boston, Massachusetts

**Richard L. Kradin, MD, DTM&H**

Associate Pathologist and Associate Physician  
Department of Pathology and Pulmonary/Critical Care Unit  
Massachusetts General Hospital  
Associate Professor in Pathology and Associate Professor in  
Medicine  
Harvard Medical School  
Boston, Massachusetts

**Gregory Y. Lauwers, MD**

Senior Member  
Department of Anatomic Pathology  
H. Lee Moffitt Cancer Center & Research Institute  
Professor of Oncologic Sciences  
University of South Florida  
Tampa, Florida

**Alice Z.C. Lobo, MD**

Dermatologist  
Clinica Alice Lobo  
Presidente Prudente, SP  
Brazil

**Eugene J. Mark, MD**

Pathologist  
Massachusetts General Hospital  
Subspecialty Head, Pulmonary Pathology  
Professor of Pathology  
Harvard Medical School  
Boston, Massachusetts

**Ricard Masia, MD, PhD**

Instructor in Pathology  
Harvard Medical School  
Assistant in Pathology  
Massachusetts General Hospital  
Boston, Massachusetts

**Martin C. Mihm Jr., MD**

Director, Melanoma Program  
Dermatology  
Director, Mihm Cutaneous Pathology Consultative Service  
Brigham and Women's Hospital  
Professor of Pathology and Dermatology  
Harvard Medical School  
Boston, Massachusetts

**Danny A. Milner Jr., MD, MSc (Epi), FASCP**

Chief Medical Officer  
Director, Center for Global Health  
American Society for Clinical Pathology  
Chicago, Illinois  
Adjunct Professor of Immunology and Infectious Diseases  
Harvard T.H. Chan School of Public Health  
Boston, Massachusetts

**Mari Mino-Kenudson, MD**

Associate Professor of Pathology  
Harvard Medical School  
Associate Pathologist  
Massachusetts General Hospital  
Boston, Massachusetts

**Joseph Misdraji, MD**

Associate Professor of Pathology  
Massachusetts General Hospital  
Boston, Massachusetts

**G. Petur Nielsen, MD**

Pathologist, Department of Pathology  
Director, Bone and Soft Tissue Pathology  
Director, Electron Microscopy  
Massachusetts General Hospital  
Professor of Pathology  
Harvard Medical School  
Boston, Massachusetts

**Nicole Pecora, MD, PhD**

Assistant Professor of Pathology and Laboratory Medicine  
University of Rochester Medical Center  
Rochester, New York

**Carlos N. Prieto-Granada, MD**

Assistant Professor  
Department of Pathology  
The University of Alabama at Birmingham  
Birmingham, Alabama

**Drucilla J. Roberts, MA, MD**

Associate Pathologist  
Massachusetts General Hospital  
Boston, Massachusetts

**Andrew E. Rosenberg, MD**

Professor of Pathology  
Vice Chair; Director of Bone and Soft Tissue Pathology  
Department of Pathology  
Miller School of Medicine, University of Miami  
Miami, Florida

**Vicki J. Schnadig, MD**

Professor Emerita  
Department of Pathology  
University of Texas Medical Branch  
Galveston, Texas

**Martin K. Selig, BA**

Senior Medical Technologist  
Massachusetts General Hospital  
Boston, Massachusetts

**Anna M. Stagner, MD**

Fellow, David G. Cogan Ophthalmic Pathology Laboratory  
Department of Ophthalmology  
Massachusetts Eye and Ear Infirmary  
Boston, Massachusetts

**Rosemary Tambouret, MD**

Department of Pathology  
Massachusetts General Hospital  
Boston, Massachusetts

**Lawrence Zukerberg, MD**

Associate Pathologist  
Massachusetts General Hospital  
Associate Professor of Pathology  
Harvard Medical School  
Boston, Massachusetts



# Preface

I am pleased to have the opportunity to publish this second edition of *Diagnostic Pathology of Infectious Disease*. For some years now, I have served as the Director of Infectious Disease Pathology at Massachusetts General Hospital. In that capacity, I have the opportunity to see a vast array of infectious diseases as they present in the practice of surgical pathology. Infectious diseases are a staple of surgical pathology, and their accurate diagnosis is critical for patient care but may be diagnostically challenging.

The nuances of the pathology of infection require the surgical pathologist to have an understanding of clinical medicine, knowledge of infectious disease demographics, experience recognizing the varied morphological features of pathogens, the ability to recognize how host responses vary with infection and immunosuppression, and the facility to know when one is not dealing with a noninfectious diagnosis. While most surgical pathologists manage to do a very reasonable job in diagnosing infection, many would likely admit that their level of sophistication in this area is limited.

Most textbooks of infectious disease pathology emphasize details of microbial identification. However, what the practicing surgical pathologist needs to know is how to recognize the morphology of organisms and the spectrum of histological responses that they may cause. Few busy pathologists have the time or inclination to specialize in infection, so they need an accessible resource on this topic. That was the rationale for the first edition of *Diagnostic Pathology of Infectious Disease*, and that aim has not changed. The present text provides new information that has accrued in this field since the last edition and has new chapters devoted to infections of the orbit and to novel techniques developed in microbiology that will assist the surgical pathologist in confirming and speciating infections.

Like the previous edition, the present text is not designed to be an in-depth compendium of infection; there are other excellent textbooks available to serve that purpose. What it *does* provide is an up-to-date, practical, and well-illustrated presentation of the pathology of infection that will be both an informational and a visual resource for the practicing surgical pathologist.

# Acknowledgments

It is difficult to know where to begin with respect to acknowledgments. Perhaps the best place is with my fellow authors who, with two exceptions, are all present or former colleagues in the Department of Pathology at the Massachusetts General Hospital (MGH).

The MGH Infectious Disease Unit is outstanding. I attend their weekly case conferences and am always impressed by the insight they bring to the diagnosis and management of challenging cases. They have been consistently supportive of the importance

of pathology in the diagnosis of infection, and I trust that I have added to their knowledge of how infection manifests in tissues.

To the staff of the London School of Hygiene and Tropical Medicine, who gave me the opportunity to hone my skills with respect to infection as a Diplomate in Tropical Infectious Disease.

To the editorial staff at Elsevier, including Bill Schmitt, who recognized the merit in this project, and Katie DeFrancesco, who has patiently shepherded it along.

# Contents

- 1 Introduction, 1**  
*Richard L. Kradin*
- 2 General Principles in the Diagnosis of Infection, 3**  
*Richard L. Kradin, Vikram Deshpande, and A. John Iafrate*
- 3 Biopsy in the Diagnosis of Infection: Clinical Approach, 16**  
*Jay A. Fishman*
- 4 Cytopathology of Infectious and Inflammatory Diseases, 22**  
*Vicki J. Schnadig*
- 5 Ultrastructural Diagnosis of Infection, 81**  
*Alton B. Farris III, Martin K. Selig, and G. Petur Nielsen*
- 6 New Technologies for the Diagnosis of Infection, 104**  
*Nicole Pecora and Danny A. Milner Jr.*
- 7 Ear, Nose, and Throat Infections, 118**  
*Matthew M. Johnson*
- 8 Pathology of Pulmonary Infection, 143**  
*Richard L. Kradin and Eugene J. Mark*
- 9 Cardiac Infections, 207**  
*Richard L. Kradin and H. Thomas Aretz*
- 10 Infections of the Gastrointestinal Tract, 232**  
*Gregory Y. Lauwers, Mari Mino-Kenudson, and Richard L. Kradin*
- 11 Liver and Bile Duct Infections, 272**  
*Ricard Masia and Joseph Misdraji*
- 12 Infectious Lymphadenitis, 323**  
*Judith A. Ferry*
- 13 Infectious Diseases of the Bone Marrow and Spleen, 352**  
*Robert P. Hasserjian and Lawrence Zukerberg*
- 14 Infection of Bone, 369**  
*Andrew E. Rosenberg, Susan V. Kattapuram, and G. Petur Nielsen*
- 15 Infections of Joints, Synovium-Lined Structures, and Soft Tissue, 404**  
*Elizabeth G. Demicco, Susan V. Kattapuram, Richard L. Kradin, and Andrew E. Rosenberg*
- 16 Genitourinary Infectious Disease Pathology, 429**  
*Alton B. Farris III and G. Petur Nielsen*
- 17 Gynecologic Infections, 468**  
*Rosemary Tambouret*
- 18 Perinatal Infections, 489**  
*Drucilla J. Roberts*
- 19 Infections of the Nervous System, 507**  
*Sandra Camelo-Piragua and E. Tessa Hedley-Whyte*
- 20 Skin Infections, 542**  
*Carlos N. Prieto-Granada, Alice Z.C. Lobo, and Martin C. Mihm Jr.*
- 21 Infections of the Eye and Its Adnexa, 648**  
*Anna M. Stagner, Frederick A. Jakobiec, Ralph C. Eagle Jr., and Norman C. Charles*
- Index, 686**

# 1

## Introduction

RICHARD L. KRADIN

Infection continues to account for the majority of human diseases. Substantial advances have occurred since the last edition of this textbook in the field of infectious disease. Technological advances have improved diagnostic yields for a variety of diseases. New diseases such as a Middle East respiratory syndrome and the Zika virus epidemic have gained worldwide attention. Global travel and the migration of large populations from Africa and the Middle East have brought populations that were previously isolated into contact. The spread of Ebola virus from 2013–2016 from areas of Africa to travelers returning to the United States highlights this issue.

Increasing numbers of therapeutic agents that modify the immune system have led to major breakthroughs in the treatment of hepatitis C, but new antiinflammatory drugs have also increased the numbers of patients who are functionally immunosuppressed. Furthermore, the phenomenon of global warming threatens to foster conditions for new and reemergent diseases.

In response to the challenge of infection, surgical pathologists must continue to render diagnoses from both cytology specimens and biopsies. Both noninvasive and minimally invasive approaches have been developed that call upon the practicing pathologist to opine with respect to smaller samples. Furthermore, in addition to establishing the cause of infection, pathologists must consider a range of disorders in their differential diagnosis with respect to underlying disorders that can mimic the histology of infection.

Whereas the microbiology laboratory and infectious disease specialists have become increasingly skilled in the diagnosis of infectious diseases, the same unfortunately has not been uniformly true of surgical pathologists, who may continue to defer to their clinical colleagues in this area. This choice is fostered by the frustration of trying to identify small numbers of small pathogens and difficulties in diagnosing organisms with accuracy. Taken together, the time, effort, and expense of diagnosing infection can at times seem nongratifying for a busy surgical pathologist.

Nevertheless, the ubiquity of infectious diseases makes it highly unlikely that surgical pathologists can avoid being confronted with the diagnosis of infection in practice, so that it behooves them to be aware of the intricacies of how infection manifests in situ. Fortunately there have been advances in this regard that will assist the surgical pathologist in establishing an accurate diagnosis. Indeed the primary aim of this new edition of the *Diagnostic Pathology of Infectious Disease* continues to be to rekindle the interest that most surgical pathologists once held for the pathologic diagnosis of infection.

The present text continues to be organized unlike most other textbooks of infectious disease pathology. The contributors continue to be subspecialists in surgical pathology who have established expertise in diagnosing the infections that primarily affect their organ system, and for this reason the text is still organized based on organ system rather than as a litany of specific infectious organisms. As a consequence, the reader will be exposed to these disorders as they are encountered in a subspecialty practice of pathology. The nuances of infectious diagnoses are presented together with their differential diagnosis, so that the reader can better glean from the text how to narrow the differential diagnosis in practice.

The text includes a preliminary discussion of the types of inflammatory responses that can be elicited by various microorganisms and how host defenses modify these responses. There is a detailed explanation of how to apply histochemical stains differentially to narrow the differential diagnosis with respect to morphology of microbes. Advances in the application of immunohistochemical stains, in situ hybridization, and polymerase chain reaction are discussed prior to a discussion of the infections encountered in the major organ systems. New chapters that specifically focus on the role of the microbiology laboratory, as well as specific infections of the orbital region, have been added to this edition.

Because many microorganisms can affect a variety of human tissues, there is necessarily redundancy within the text with respect to their description. However, on balance, the superimposed constraints of tissue microanatomy lead to diversity with respect to the morphologic appearances of infection at different sites, so that repetitiveness in this regard has a didactic purpose. In addition, for the busy practitioner, it is possible to use this text as a single resource with respect to infection in an organ system of specific interest, in a case-dependent fashion, without having to consult a series of subspecialty texts.

As conceived, the present text is still designed to be functionally complete but not encyclopedic, and there is much information with respect to the clinical, epidemiologic, or mechanistic bases of infection that will not be found here. In addition, some exotic parasitic disorders have not been included. Other texts that include these data are available, and at times a pathologist may need to refer to them. However, for the most part, all that is required to diagnose the vast majority of infections can be found within the present revised text.

The diagnosis of infection, comparable to that of neoplasia, requires experience. The morphologic appearances of infection are

as diverse as those of malignancy. Because the variations encountered are virtually inexhaustible, no textbook can expect to illustrate all of what is encountered in practice. Indeed, at times textbooks tend to focus on one aspect of an infection and the inexperienced pathologist in this area may be misled in expecting to encounter examples that are comparable to those within

selected illustrations. This text cannot replace experience. However, after the diverse appearances of infection are appreciated and accepted, the surgical pathologist may derive substantial pleasure from pondering their fine distinctions and take pride in the growing sense of competence that develops from his or her experience in this area.

# 2

## General Principles in the Diagnosis of Infection

RICHARD L. KRADIN, VIKRAM DESHPANDE, A. JOHN IAFRATE

### Sampling

#### Diagnosing Infection In Situ

#### Potential Limits of Biopsy Interpretation

#### Classification of Patterns of Infection

#### Histochemical Stains

Hematoxylin and Eosin

Gram Stain

Silver Impregnation

Fungal Stains

Acid-Fast Bacteria Stains

Connective Tissue Stains

Giemsa Stains

Mucicarmine

Melanin Stains

Viral Inclusion Body Stains

#### Immunohistochemical Methods

#### Molecular Diagnostics

#### In Situ Hybridization

Polymerase Chain Reaction

Branch Chain In Situ Hybridization

The identification of infection in biopsied tissues is the primary responsibility of the surgical pathologist. In an age when both noninvasive and minimally invasive approaches and techniques have increased, it is important to revisit the role of the biopsy in the diagnosis of infection (Box 2.1). Isolating microorganisms in the microbiology laboratory is a sensitive and accurate approach to their identification, but it has several important limitations. First, it cannot distinguish infection from colonization, nor can it ascertain the significance of the isolated organism. Only the presence of an organism in situ, together with an expected inflammatory response by the host, constitutes acceptable evidence of its role in infection.

For example, consider how to interpret the clinical significance of a fungus isolated from the airways of a patient with bronchiectasis who also has a new pulmonary infiltrate in the setting

of immunosuppression. Is the fungal isolate the likely cause of the opportunistic infection, or might it be a benign commensal? Studies have attempted to address this question<sup>1</sup> with guidelines formulated for practice, but these are indeed merely “guidelines” because only identification of a potential pathogen within a site of infection can provide substantive evidence that the fungus is an invasive pathogen. For this and other reasons to be addressed in this text, the pathologic diagnosis of infection is a critical element in formulating optimal therapy.

### Sampling

Tissue sampling is fundamentally important in the diagnosis of infection. All excised tissues should be considered as potentially infective. This approach fosters due diligence with respect to the possibility of contagion, as well as thoughtful concern as to how the tissues will be handled to optimize the chances of establishing an accurate diagnosis (Box 2.2). Samples of excised tissues should be harvested by sterile technique and sent to the microbiology laboratory with information concerning the types of organism that are being considered diagnostically. Directions to consider anaerobic and fastidious species should be clearly stated.

The surgical pathologist must ascertain that all diagnostic possibilities have been considered. Consultation with an infectious disease specialist can be invaluable in ensuring that specimens are properly handled ab initio. What must be avoided is thoughtlessly placing a biopsy specimen directly into formalin fixative without first considering a diagnosis of infection.

Touch imprints should be routinely prepared and can be stained in the frozen-section suite or in the microbiology laboratory. In general, 5 to 10 touch imprints will suffice, with sampling from the most suspicious portions of the biopsy specimen (e.g., areas of necrosis or suppuration).

Harvesting a portion of the biopsy specimen for ultrastructural analysis can foster the accurate diagnosis of many organisms (e.g., viruses, *Tropheryma whippeli*, microsporidia).<sup>2</sup> Specimens may be harvested for polymerase chain reaction (PCR) testing to establish the diagnosis of others (e.g., *Coxiella*, *Mycobacterium*, *Rickettsia*).<sup>3</sup>

The rapid diagnosis of a frozen section can help to focus on the diagnostic workup. All of the pertinent histochemical and ancillary studies can ideally be ordered before the permanent sections are processed, to avoid undue delay in diagnosis.



### • BOX 2.1 Role of the Surgical Pathologist in the Diagnosis of Infection

Establish morphologic diagnosis of infection  
 Assess immunocompetence of the host  
 Narrow the differential diagnosis of possible pathogens  
 Confirm results of microbiologic cultures  
 Refute the relevance of microbiologic cultures  
 Establish diagnosis unrelated to infection  
 Identify concomitant infection in a primary inflammatory or neoplastic disorder  
 Identify new pathogens

### • BOX 2.2 Optimal Handling of Tissue Biopsies: Always Consider Infection!

Make touch imprints for histochemical staining  
 Handle samples for microbiologic culture with sterile technique  
 Harvest samples for ultrastructural examination in glutaraldehyde fixative  
 Harvest fresh samples for appropriate polymerase chain reaction assays  
 Freeze portion of biopsy specimen for research  
 After all of this is done, place biopsy specimen in formalin

## Diagnosing Infection In Situ

Because host immune mechanisms can greatly amplify the host response, the actual number of pathogens present in tissues is frequently surprisingly small. This means that many sections may need to be examined before a pathogen is identified. Although few surgical pathologists would balk at the idea of ordering additional sections to exclude malignancy in a biopsy they deemed suspicious, it is not uncommon for a pathologist to examine only a single histochemically stained tissue section in the diagnostic process of infection.<sup>4</sup> More egregious is the fantasy that the causative infectious agent will eventually be diagnosed by the microbiology laboratory, so there is no need for the surgical pathologist to belabor the process.

This approach is wrong minded for several reasons. First, the microbiology laboratory may fail to identify a causative organism.<sup>5</sup> Second, the organism isolated by the laboratory may not represent the actual infective agent *in vivo*. The analogy is the role for Gram staining of secretions in chronically intubated patients to determine whether there is a neutrophilic exudate consistent with infection and whether there is a predominating organism—steps that can promote the choice of appropriate antibiotic therapy.<sup>6</sup> In this setting, undue emphasis on culture results can lead to a seemingly endless process of adding or eliminating antibiotics in patients who are merely colonized by bacteria and not actually infected. Treatment decisions that do not take into account the host response and dominating organisms will tend to favor the production of increasingly antibiotic-resistant isolates and may potentially compromise public health. This is only one of several compelling reasons to consider diagnostic biopsies in patients with infections in situations that do not readily yield to noninvasive approaches.

## Potential Limits of Biopsy Interpretation

Despite the merits of examining biopsy specimens in the diagnosis of infection, one must be aware of those situations in which the

TABLE 2.1 Tissue Responses to Infection

Type of Inflammation	Example
Exudative inflammation	Pyogenic bacteria
Necrotizing inflammation	Gram-negative bacteria, amebiasis
Granulomatous inflammation	Mycobacteria, fungi
Histiocytic inflammation	<i>Rhodococcus</i> , <i>Legionella</i> , Whipple disease
Eosinophilic inflammation	Fungi, parasites
Cytopathic changes	Viruses
No response	Host energy


sensitivity and specificity of histochemically stained sections are limited. An example is tuberculosis, in which biopsies can fail to demonstrate mycobacteria in almost half of cases.<sup>7</sup> However, even in this setting, the appearance of the inflammatory response *in situ* should foster a working diagnosis that is often sufficiently reliable to institute empirical treatment.

## Classification of Patterns of Infection


There is currently no uniformly accepted classification schema for the histologic patterns of response yielded by microorganisms. The inflammatory response in infection is a function of the host response, which is in turn a function of (1) the anatomy of the affected organ, (2) the virulence factors produced by the infective agent, and (3) host immunocompetence. The surgical pathologist must be aware that a single species of microorganism may be capable of evoking a variety of different patterns of inflammation. An example is the broad spectrum of disorders produced in response to infection with *Aspergillus* spp., which ranges from benign colonization, to hypersensitivity responses, to malignant angioinvasive infection.<sup>8</sup>

The characteristic types of inflammation elicited by infection (Table 2.1) can be broadly categorized as follows.


1. **Pyogenic responses.** In these responses, neutrophils predominate, leading to pus formation. They are evoked primarily by bacteria, although viruses and fungi can also elicit them (Fig. 2.1).
2. **Necrotizing inflammation.** Tissue necrosis can occur in several forms. In certain infections, such as those caused by amoebas or gram-negative bacteria, liquefactive necrosis is frequently seen (Fig. 2.2). Other forms, such as ischemic, mummefactive, and caseous necrosis, are often seen in mycobacterial and fungal infections.
3. **Granulomatous inflammation.** This response is characterized by the presence of epithelioid macrophages with multikaryon (giant cell) formation. It appears to reflect cell-mediated immunity to poorly catabolized antigens and is evoked by mycobacteria, fungi, and parasites (Fig. 2.3).
4. **Histiocytic inflammation.** These responses are characterized primarily by the presence of foamy macrophages and are a prominent component of infections caused by *Legionella*, *Rhodococcus*, *Calymmatobacterium*, *Leishmania*, and *T. whippeli* (Fig. 2.4). In patients who are severely immunocompromised,




• **Figure 2.1** Pyogenic response in acute infective endocarditis due to *Streptococcus* spp. with neutrophilic exudate (x400).




• **Figure 2.4** Histiocytic response shows “foamy” macrophages containing *Leishmania donovani* (arrow) (x600).



• **Figure 2.2** Necrotizing response to *Pseudomonas aeruginosa*, showing liquefactive destruction of lung tissue (x250).



• **Figure 2.5** Eosinophilic response to *Aspergillus fumigatus* (x400).




• **Figure 2.3** Granulomatous response to *Mycobacterium tuberculosis* (x25).

organisms that normally elicit granulomatous inflammation may instead evoke histiocytic infiltrates.


5. **Eosinophilic inflammation.** This is seen in response to multicellular parasites and certain fungi (Fig. 2.5).
6. **Cytopathic changes.** Although this is not properly a type of inflammation, cytopathic changes do reflect a response to viral infection. Nuclear inclusions are part of the response to DNA viruses, whereas cytoplasmic inclusions are seen with some RNA and DNA viral infections, such as cytomegalovirus (Fig. 2.6).
7. **Null responses.** In the setting of profound immunosuppression, one may not see inflammation; only the uninhibited growth of microorganisms is apparent (Fig. 2.7).

This classification schema is only a crude approximation because overlap patterns of inflammation are common, as with necrotizing granulomatous inflammation, granulohistiocytic inflammation (Fig. 2.8), and granulomatous inflammation with tissue eosinophilia (Fig. 2.9). The primary didactic element is that careful consideration of the histologic response in situ can help to narrow what would otherwise be a very broad differential diagnosis and can also provide invaluable information concerning host immunocompetence. For this reason, surgical pathologists must develop expertise concerning the inflammatory patterns that can accompany reduced immunocompetence resulting from genetic







• **Figure 2.6** Cytopathic response to *Cytomegalovirus* with both nuclear and cytoplasmic (arrow) inclusions (x600).



• **Figure 2.7** Null response to *Cryptococcus neoformans* (arrows) (x400).



• **Figure 2.8** Granulohistiocytic response to *Blastomyces dermatitidis* (x250).



• **Figure 2.9** Granulomatous response with tissue eosinophilia due to *Coccidioides immitis* (x250).

factors, age, toxins, and drugs, because they can skew the expected pattern of inflammation and at times confound the diagnosis.

## Histochemical Stains

The identification of microorganisms in biopsy samples is enhanced by the selective application of widely available histochemical stains (Table 2.2). Pathologists should be aware of the spectrum of histochemical staining by microorganisms and knowledgeable with respect to how to formulate combinations of stains to enhance diagnostic specificity.<sup>9</sup>

## Hematoxylin and Eosin

The majority of pathogens can be identified with the standard hematoxylin and eosin (H&E) stain. These include cytopathic viruses, some bacteria, most fungi, and virtually all parasites (Box 2.3).

## Gram Stain

The tissue Gram stain is a congener of the Gram stain used routinely to identify organisms in body secretions and fluids. The Brown-Hopps stain is currently the preparation of choice because it enhances gram-negative bacteria and rickettsia to a greater degree than the Brown-Brenn. In addition, the latter can be hazardous to technical personnel and has largely fallen into disfavor. The tissue Gram stain colors the cell walls of gram-positive bacteria a deep violaceous blue (Fig. 2.10A) and gram-negative bacteria a pale salmon pink (see Fig. 2.10B). Consequently, it is far easier to detect gram-positive species, and one must be careful not to overlook the presence of faintly stained gram-negative species. Gram variability is a potential pitfall in interpretation because it can raise the specter of polymicrobial infection. Attention to the uniform morphologic characteristics of stained organisms is the best way to avoid being misled by this phenomenon.

Nonbacterial pathogens can also be identified with the Gram stain. The blastoconidia (yeast) of *Candida* spp. (Fig. 2.11A) and the microconidia of *Aspergillus* spp. (see Fig. 2.11B) are gram positive, and this feature can help in distinguishing these species from other fungi. Microsporidia can be well demonstrated as gram-positive intracellular inclusions within cells (Fig. 2.12).

**TABLE 2.2** Histochemical Staining Characteristics of Microbes

Organism	Staining Characteristics
<b>Viruses</b>	
Influenza	No cytopathic change
Coronavirus (SARS)	No cytopathic change
Adenovirus	H&E (smudge cells); IHC
Cytomegalovirus	H&E (intranuclear and cytoplasmic inclusions); IHC; PAS and GMS (intracytoplasmic inclusions)
Herpes virus	H&E (intranuclear inclusions); IHC
Measles	H&E (intranuclear inclusions, polykaryons)
Respiratory syncytial virus	H&E (polykaryons); IHC
Parainfluenza	H&E (intracytoplasmic inclusions)
<b>Bacteria</b>	
Gram positive	Tissue Gram, GMS (all)
Gram negative	Tissue Gram, GMS (some)
<i>Legionella</i>	Silver impregnation
<i>Nocardia</i>	Tissue Gram, GMS, modified ZN
<i>Actinomyces</i>	Tissue Gram, GMS
<i>Mycobacteria tuberculosis</i>	ZN and modified ZN; PCR
Atypical mycobacteria	Modified ZN, $\pm$ ZN, PCR
<b>Fungi</b>	
<i>Histoplasma</i>	GMS, PAS
<i>Cryptococcus</i>	H&E, GMS, PAS, mucicarmine; Fontana, IHC
<i>Blastomyces</i>	H&E, GMS, PAS, mucicarmine (weak)
<i>Coccidiomyces</i>	H&E, GMS, PAS
<i>Candida</i>	H&E, GMS, PAS, Gram stain; IHC
<i>Aspergillus</i>	H&E, GMS, PAS, IHC
<i>Zygomycetes</i>	H&E, GMS, PAS
<i>Pseudoallescheria</i>	H&E, GMS, PAS
<i>Alternaria</i> and dematiaceous fungi	H&E, GMS, PAS, Fontana
<b>Parasites</b>	
Protozoa	H&E, PAS, Gram stain (microsporidia); IHC ( <i>Toxoplasma</i> )
Metazoans	H&E, trichrome stain
<i>Echinococcus</i>	GMS in chitinous wall, modified ZN (hooklets)
Paragonimiasis	Ova birefringent
Schistosomiasis	Lateral and terminal spines stain with modified ZN

GMS, Gomori methenamine silver stain; H&E, hematoxylin and eosin stain; IHC, immunohistochemical methods; PAS, periodic acid–Schiff stain; PCR, polymerase chain reaction; SARS, severe acute respiratory syndrome; ZN, Ziehl–Neelsen stain.

### • BOX 2.3 Microbes That Can Be Identified With Hematoxylin and Eosin Stain

Cytopathic viruses  
Bacteria in colonies or in “granules”  
Most fungi  
Parasites

## Silver Impregnation

The impregnation of tissue sections with silver constitutes the basis of the Warthin–Starry, Dieterle, and Steiner stains. There is some controversy among experts as to whether these stains are equally efficacious in the identification of certain organisms, such as *Bartonella* spp., but they generally yield comparable results. In theory, all eubacteria, including mycobacteria, will stain positively with silver impregnation. However, in our experience, they do not do so reliably, and this approach cannot be recommended as a screening tool. In general, bacteria are enhanced both colorimetrically and in size by the deposition of silver salts on their cell walls, making them easier to identify but at times causing confusion in interpretation. Background staining presents a problem in interpretation, but the morphologic regularity of eubacteria usually allows for accurate identification after experience has been established with the technique.



Certain weakly gram-reactive or non-gram-reactive bacteria cannot be demonstrated reliably by any other histochemical method. These include *Treponema* spp. (Fig. 2.13), *Borrelia* spp., *Bartonella* spp., *Leptospira* spp., and *Calymmatobacterium*. Weakly staining gram-negative bacteria, including *Legionella* spp., *Burkholderia* spp., *Francisella* spp., and *Helicobacter*, are also best demonstrated by silver impregnation.

## Fungal Stains


The Gomori methenamine silver (GMS) and Gridley stains are the preferred methods for demonstrating fungi (Table 2.3). Because certain fungi demonstrated by GMS do not consistently stain well with periodic acid–Schiff (PAS), the latter should be reserved as a secondary approach, but it can at times enhance morphologic detail. Although the GMS is often counterstained with methyl green for contrast, other counterstains can be applied. For example, it is possible to counterstain with H&E; this allows for a detailed assessment of the cellular immune response and promotes accurate identification of intravascular and perineural invasion by organisms.

All gram-positive bacteria, including the actinomycetes, stain with GMS (Fig. 2.14), as do some encapsulated gram-negative bacteria, such as *Klebsiella* spp. Bacteria that have been treated before tissue sampling (e.g., infective endocarditis) may not be well decorated by the Gram stain, but they often retain their GMS positivity. For this reason, both stains should be examined before excluding a gram-positive bacterial infection. The actinomycetes, including mycobacteria, are gram-positive eubacteria and consequently also stain with GMS. The GMS is the stain of choice for demonstrating *Pneumocystis jirovecii* (Fig. 2.15), and it highlights the trophozoites of *Entamoeba histolytica*, encysted amoebas, the intracytoplasmic inclusions of cytomegalovirus-infected cells, the polar bodies of microsporidia, and the cyst wall of *Echinococcus* spp. (Fig. 2.16).







• **Figure 2.10** **A**, *Streptococcus* spp. stain deep blue-magenta ( $\times 600$ ). **B**, Gram-negative bacteria are pale salmon-pink (arrows) ( $\times 600$ ).




• **Figure 2.11** The microconidia of *Aspergillus fumigatus* stain intensely gram positive ( $\times 250$ ).



• **Figure 2.12** Gram-positive intracytoplasmic microsporidia ( $\times 400$ ).




• **Figure 2.13** Spirochetes of *Treponema pallidum* stain with Warthin-Starry silver impregnation ( $\times 400$ ).




• **Figure 2.14** *Actinomyces israelii* stains with Gomori methenamine silver ( $\times 250$ ).

**TABLE 2.3** Fungal Identification in Tissue

Organism	Size (Width in $\mu\text{m}$ )	Defining Morphology
<i>Histoplasma capsulatum</i>	2-5	Narrow-neck bud
<i>Cryptococcus neoformans</i>	5-20	Narrow-neck bud
<i>Blastomyces dermatitidis</i>	15-30	Broad-based bud
<i>Candida glabrata</i>	3-5	Budding, no pseudohyphae
<i>Candida</i> spp.	2-3	Yeast, pseudohyphae, hyphae
<i>Aspergillus</i> spp.	3-5	Acute-angle branching, septate, conidial head
<i>Zygomycetes</i> spp.	5-8	Right-angle branching, ribbons, pauciseptate
<i>Pseudallescheria</i> spp.	3-4	Acute-angle branch, septate, terminal chlamydospore, pigmented conidia
<i>Fusarium</i> spp.	4-5	Acute and right-angle branch, septate, narrowed branch points
<i>Coccidioides immitis</i>	20-200	Endosporulation



• **Figure 2.15** Gomori methenamine silver-positive cysts of *Pneumocystis jirovecii* ( $\times 600$ ).



• **Figure 2.16** Gomori methenamine silver-positive wall of cyst produced by *Echinococcus granulosus* ( $\times 200$ ).

### Acid-Fast Bacteria Stains

The Ziehl-Neelsen (ZN) stain and its modifications historically have been essential tools in the identification of mycobacteria.<sup>3</sup> *Mycobacterium* spp. (Fig. 2.17A) are also GMS positive (see Fig. 2.17B), and some atypical mycobacteria, such as *Mycobacterium avium-intracellulare* complex (MAC), also stain with PAS. The modified stain for acid-fast bacteria (Fite-Faraco or Putt) detects mycobacterial antigens that are sensitive to strong acid, a step in the decolorization of the ZN stain. For this reason, it can be used to screen for all mycobacteria and may be required to detect certain atypical mycobacteria, such as *Mycobacterium leprae*, as well as *Nocardia*, *Rhodococcus*, and *Legionella micdadei*. The cortical spines of *Schistosoma* spp. (Fig. 2.18), the hooklets of *Echinococcus*, and the spores of *Cryptosporidium* also stain well, but variably, with modified acid-fast bacillus stains.

### Connective Tissue Stains

Masson trichrome, Movat pentachrome, and Wilder reticulin stains can be useful ancillary methods for classifying helminthic infections (Fig. 2.19). The inclusions of cytomegalovirus are demonstrated well by trichrome stains. The reticulin stain demonstrates the details of most helminths, the amastigotes of trypanosomes, and the rod-shaped kinetoplast of *Leishmania* spp.



### Giemsa Stains

Giemsa stains and their variants can help in identifying a wide spectrum of pathogens, including protozoa, bacteria, chlamydia, and rickettsia. However, the small size of some of these organisms (e.g., rickettsiae) limits the degree of confidence in establishing an accurate diagnosis, and prior experience in diagnosing these infections is essential.<sup>10</sup>


### Mucicarmine

Several fungi, most notably *Cryptococcus*, *Blastomyces*, and *Rhinosporidium*, exhibit mucicarmineophilia, either in their secreted capsules (*Cryptococcus*) or in their cell walls. Mucicarmineophilia







• **Figure 2.17** *Mycobacterium tuberculosis* stains with Ziehl-Neelsen stain ( $\times 600$ ) (A) and Gomori methenamine silver stain ( $\times 600$ ) (B).



• **Figure 2.18** Cortical spine of ovum of *Schistosoma mansoni* stains positive with Fite-Faraco stain ( $\times 600$ ).



• **Figure 2.20** Mucicarmine stain decorates the capsule of *Cryptococcus neoformans* ( $\times 400$ ).



• **Figure 2.19** Wilder reticulin stain highlights *Dirofilaria immitis* ( $\times 150$ ).

is an essential feature in the diagnosis of *Cryptococcus*; however, this staining, although invariably present, may be difficult to detect in capsule-deficient variants (Fig. 2.20).<sup>11</sup>


### Melanin Stains

The Fontana-Masson stain demonstrates premelanin precursors within the cell wall of *Cryptococcus neoformans* and is an essential confirmatory approach to the in situ identification of capsular-deficient forms (Fig. 2.21).<sup>12</sup> All dematiaceous fungi are positive with Fontana-Masson, and this stain can help to confirm the impression of pigmentation seen in H&E sections.

### Viral Inclusion Body Stains

A number of stains (e.g., Feulgen) can detect viral inclusions with cells. However, none add considerably to the H&E stain in this regard, and they are rarely adopted in practice, especially since confirmatory immunostains have become more widely available.





• **Figure 2.21** Fontana-Masson stain assists in the identification of an “acapsular” variant of *Cryptococcus neoformans* ( $\times 400$ ).

**TABLE 2.4 Immunohistochemical Stains Commercially Available for Microbe Identification in Paraffin-Embedded Tissues**

Fungi	Viruses and Bacteria
<i>Aspergillus</i> (genus only)	Herpes virus 1 (cross-reacts herpes virus 2)
<i>Cryptococcus</i>	Varicella zoster
<i>Histoplasma</i>	Cytomegalovirus
<i>Candida</i> spp.	Respiratory syncytial virus
<i>Coccidioides immitis</i>	Adenovirus
<i>Pneumocystis jiroveci</i>	Epstein-Barr (Epstein-Barr-encoded RNA)
<i>Pseudallescheria boydii</i>	Actinomycetes
Zygomycoses (genus only)	<i>Actinomyces israelii</i>
<i>Sporothrix schenckii</i>	<i>Actinomyces naeslundii</i>
<i>Trichosporon</i>	<i>Arachnia propionica</i>

## Immunohistochemical Methods

A large number of immunostains are available that can be helpful in the identification of microorganisms (Table 2.4).<sup>13</sup> Many of these are commercially available and currently enjoy wide popularity in diagnostic pathology laboratories. Others are available reliably only at highly specialized centers, such as the Centers for Disease Control and Prevention. Development of new immunohistochemical techniques can be a worthwhile but labor-intensive task. Because there is wide cross-reactivity among fungal species and among bacteria, it is critical to establish the potential cross-reactivity of any new antibody and its relative specificity.<sup>14</sup> Nevertheless, it may at times be possible to limit the use of a reagent to a narrow range of differential diagnostic possibilities (e.g., to distinguish *Aspergillus* spp. from *Pseudallescheria boydii* infection).

## Molecular Diagnostics

Molecular techniques continue to dramatically reshape clinical microbiology practice. Currently, molecular techniques involving the identification of microbial nucleic acids are critical to the management of a growing number of infectious agents, most importantly the chronic viral infections, including human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus. HIV management is a prototype for the implementation of molecular medicine because the diagnosis can be made using reverse transcriptase–polymerase chain reaction (RT-PCR) amplification of viral RNA, antiviral therapy regimens can be adjusted based on serial RT-PCR viral load measurements, and resistance mutations can be detected by sequencing of the viral genes targeted by current drugs (protease and reverse transcriptase inhibitors).


In the setting of surgical pathology a role is beginning to be developed for molecular techniques in the pathologic assessment of infection. The most relevant techniques in the setting of tissue diagnosis are in situ microbial detection using nucleic acid probes (in situ hybridization [ISH]) and PCR using nucleic acids purified from tissue sections. These two techniques can allow for diagnosis when special stains and immunohistochemical stains are insensitive (e.g., low antigen expression), and in some instances they can allow for speciation when microbes are identified with those techniques. In addition, molecular identification can accelerate definitive diagnosis with organisms that grow slowly or not at all in culture (e.g., fastidious organisms such as mycobacteria).

## In Situ Hybridization

ISH is a technique that uses fluorescent or radiolabeled nucleic acid probes to recognize specific microbial sequences in tissue sections. The probes contain RNA or DNA sequences complementary to the target genetic elements and allow for specific localization of microbes in tissue or within cells. Depending on the sequence, some ISH probes can also bind specifically to nucleic acids from individual species, allowing for differentiation of organisms with variable virulence. Although there is great specificity with many ISH probes, immunohistochemistry is preferred, if possible, because of ease of incorporation into the modern automated pathology laboratory.

Most critical to the surgical pathologist is the identification of human papillomavirus (HPV) infection in cervical cancer screening, and this is most often accomplished with the use of PCR or similar techniques from liquid Pap smear specimens. ISH can also be very effective for definitive detection of high-risk HPV subtypes in cervical biopsy analysis for dysplasia and in defining HPV status of oropharyngeal squamous cell carcinomas.<sup>15</sup> Immunohistochemistry for HPV antigens has not proved sensitive enough (although p16 positivity is a reasonable surrogate marker of HPV infection). The HPV genome is present as episomes in low-grade lesions, so ISH reveals diffuse and intense staining (Fig. 2.22). In high-grade lesions and invasive carcinomas, the HPV genome integrates into the host genome, and ISH reveals a punctate nuclear signal.

ISH is also useful in the detection of Epstein-Barr virus (EBV) in lymphocytes, including in lymphoproliferative disorders, because the EBV-encoded RNAs (EBER1 and EBER2) are expressed at very high levels. Commercial EBER ISH assays have been developed and are automatable.



• **Figure 2.22** A, Human papillomavirus (HPV) infection is manifested by viral genomes present as A1 episomes or as A2 integrated DNA. Therefore in situ hybridization (ISH) probes give diffuse (*lower right*) or discrete (*lower left*) staining patterns in HPV-positive tissue. Actual ISH is shown in two oropharyngeal squamous cell carcinomas, with episomal signals (**B**) and integrated virus (**C**). (Photographs courtesy of Dr. Jennifer Hunt, Cleveland Clinic Department of Pathology.) (x250).

In 2016, a novel chemical variant of DNA called peptide nucleic acids (PNAs), consisting of nucleoside bases joined by a peptide backbone rather than a sugar backbone, has been used to detect microbial genetic material. PNA probes offer the advantage of chemical stability and higher sensitivity and specificity. These properties offer the opportunity of developing probes that can differentiate species in situ. Such probes have proved successful in differentiating tuberculous from nontuberculous mycobacterial infections by targeting the 16S ribosomal RNA; others have detected *Staphylococcus aureus*, *Enterococcus faecalis*, and *Candida* species.<sup>16-19</sup>

## Polymerase Chain Reaction

PCR amplification to detect infectious agents in surgical pathology specimens is now so common that a basic description of the technique is unnecessary.<sup>20,21</sup> PCR is without a doubt the most sensitive detection method available, and because it can be performed on archived formalin-fixed, paraffin-embedded samples, important diagnoses can be rendered even if cultures were not obtained from tissue biopsies at the time of processing (e.g., lung wedge resections for tumor that later reveal necrotizing granulomas). Common applications of PCR to surgical samples are listed in [Table 2.5](#).

However, central to PCR is the requirement that the exact RNA or DNA sequences to be amplified must be known. Abundant microbial sequence data are publicly available, so that any equipped laboratory can analyze the most known pathogens.

**TABLE 2.5** Applications of the Polymerase Chain Reaction to Microbial Detection in Tissues

Organism	Pathologic Process
<i>Aspergillus</i>	Invasive aspergillosis <sup>21</sup>
Human papillomavirus	Cervical HSIL and LSIL, HPV-positive squamous cell carcinoma of the oropharynx
Herpes virus	Herpes encephalitis (CSF or brain biopsy)
Mycobacteria	Necrotizing granulomatous inflammation
Bartonella	Cat-scratch disease or bacillary angiomatosis
Enterovirus, adenovirus, influenza A virus	Viral myocarditis <sup>20</sup>

CSF, Cerebrospinal fluid; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.

There are a number of well-conserved genes in microorganisms, such as the ribosomal 16S gene and the heat shock protein/chaperonin HSP60/65 (or GroEL), that are excellent targets for PCR. Analysis of the 16S ribosomal RNA gene in bacteria by PCR and subsequent sequencing is especially informative because there are well-conserved sequences that can be used as binding sites for



universal PCR primers adjacent to variable sequences and then analyzed and compared with databases of known sequences (Fig. 2.23).


This sensitivity of PCR is not without its problems. Many of the most important infectious agents seen in general practice are found in the environment and can contaminate surgical specimens. For example, *Aspergillus* and mycobacterial species are normal denizens of the clinical laboratory; if samples are not kept sterile, they may come in contact with these species during tissue processing. Even more vexing, such species also can cause opportunistic infections, and so their identification cannot always be dismissed as clinically irrelevant.

### Branch Chain In Situ Hybridization

A branch chain in situ hybridization (bISH) assay is yet another platform for detecting infectious organisms in formalin-fixed, paraffin-embedded tissue (Fig. 2.24).<sup>22</sup> This technology uses a branched DNA structure for signal amplification, but, unlike PCR, the target is not amplified. The signal amplification greatly



increases the sensitivity of the assay, although it is significantly lower than PCR-based techniques. Multiple tiling probes for a gene are hybridized to the target RNA, and these are typically distributed throughout the genome of interest, greatly increasing the sensitivity of the assay. A signal amplification structure is created by a series of hybridization steps. The final steps involve hybridization of multiple alkaline phosphatase–conjugated label probes, and the eventual branched structure has approximately 400 binding sites for the alkaline phosphatase–labeled probe, which can be visualized as a red chromogen with a bright field microscope. The signal is typically seen as dots, although with highly expressed transcripts individual dots are no longer visualized. These assays are commercially available and can be performed on clinical grade automated immunohistochemistry instruments.

Although it is theoretically possible to develop probes against virtually any organisms, the bISH assay is generally successful in cases in which the target is highly expressed, such as EBV, cytomegalovirus (CMV), and high-risk (HR) HPV infections. The bISH assay detects E6 and E7, transcripts that are highly expressed




• **Figure 2.23** Two cases of mycobacterial infection. **A**, *Mycobacterium avium-intracellulare* complex (MAC) infection in a lung specimen with **(B)** numerous acid-fast bacteria (AFB). **C**, Lung specimen with *Mycobacterium tuberculosis* complex (MTb) infection with rare AFB (arrow in **D**) (×200).

*Continued*




F



G

- **Figure 2.23, cont'd** DNA was isolated from formalin-fixed, paraffin-embedded tissue and amplified with primers to the *HSP65* gene, showing positive bands for the MTb sample (**E**, lane 1) and the MAC sample (**E**, lane 2). An MTb-specific gene polymerase chain reaction assay (*IS6110* gene) reveals a band with only MTb (**E**, lane 4). Water-only control lanes show no band in either reaction (**E**, lanes 3 and 6). The *HSP65* gene products were subject to DNA sequencing with the bacterial sequence from the MTb sample in **F** and from the MAC in **G**. Alignment of the two sequences reveals numerous sequence differences (*arrows*) in the region, which can be used to differentiate the two species.



- **Figure 2.24** This bISH RNA assay for high-risk HPV targets HPV-16 E6 and E7 transcripts. The red chromogen in this head and neck squamous cell carcinoma is noted within both the nucleus and the cytoplasm.